MARCH 1, 2017

Palto Alto, CA

ILLUSTRIS LAUNCHES NOVEL TECHNOLOGY AND ANNOUNCES VETERAN INDUSTRY LEADERSHIP

Illustris Pharmaceuticals, Inc. today announced the formation of its leadership team to launch its revolutionary delivery technology platform.  The leadership team consists of Jonah Shacknai, former CEO of Medicis, Mark Prygocki, former President of Medicis, Dr. Jacob Waugh, Co-Founder Revance, Dr. S. K. Tan, founding member of Derma-Rx and IDS Clinic and one of the foremost physicians in aesthetics and cosmeceuticals in Asia, and Andrew Hirschberg, a 25 year veteran of pharmaceutical industry investment banking.  This experienced management team will focus on licensing opportunities for companies seeking to enable or optimize the delivery of their active ingredients through tissue structures such as skin, eyes and mucosal surfaces.

“We are pleased to have assembled a world-class leadership team to introduce Illustris’ innovative delivery technology,” said Jonah Shacknai, Chairman of Illustris. "We believe the Illustris family of technologies provides a significant competitive advantage with its novel approach to molecule delivery, yielding enhanced safety and efficacy for patients.  We are eager to introduce the Illustris technology to the wider industry, and showcase it’s significant advantages over current delivery platforms.”

The Illustris technology platform both enables the delivery of large molecules (up to 160KD) through tissue structures and optimizes the absorption of compounds typically delivered through skin, eyes and mucosal surfaces. The Illustris technology platform facilitates the delivery of active ingredients through tissue structures by deploying decoys, many of which temporarily distract and relax anchors that bind tissue cells together, providing a portal for active ingredients to permeate the targeted site.  Based on the clinical objective, Illustris can deploy the appropriate amount of decoy to fully penetrate or partially permeate the targeted tissue structure or organ system.  The Illustris proprietary platform enables the delivery through tissue structures of macromolecule active ingredients (up to 160KD) which are historically difficult or impossible to deliver topically, and optimizes delivery of active ingredients which previously permeated tissue structures inefficiently.  Illustris has filed broad patent applications across several classes of applications and compounds.